Molecular mechanisms of enzalutamide resistance in prostate cancer

被引：14

作者：

Blatt, Eliot B. ^{[1
]}

Raj, Ganesh, V ^{[1
,2
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA

[2] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA

来源：

CANCER DRUG RESISTANCE | 2019年 / 2卷 / 02期

关键词：

Drug resistant cancers; resistance modulation; biomarkers of drug responsiveness; targeted therapy resistance; EPITHELIAL-MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR COACTIVATOR; SPLICE VARIANTS; GLUCOCORTICOID-RECEPTOR; THERAPEUTIC RESISTANCE; LINEAGE PLASTICITY; TARGET GENES; CELL-GROWTH; LNCAP CELLS; ANTIANDROGEN;

D O I：

10.20517/cdr.2019.25

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year due to the development of therapy resistance, most notably resistance to second-generation antiandrogen enzalutamide. The vast majority of PCa is driven by the androgen receptor (AR). Enzalutamide is an AR antagonist, which extends patient survival and is widely used in the clinic for the treatment of castration-resistant prostate cancer (CRPC); however, many patients will have primary or develop acquired resistance and continue to progress. Characterization of the molecular mechanisms of enzalutamide resistance provides insight into potentially efficacious therapies for enzalutamide-resistant CRPC (ER-CRPC). Understanding these mechanisms is critical for the identification of biomarkers predictive of therapy resistance and the development of therapeutic strategies to target ER-CRPC.

引用

页码：189 / 197

页数：9

共 88 条

[11] Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer [J].

Azad, Arun A. ;

Volik, Stanislav V. ;

Wyatt, Alexander W. ;

Haegert, Anne ;

Le Bihan, Stephane ;

Bell, Robert H. ;

Anderson, Shawn A. ;

McConeghy, Brian ;

Shukin, Robert ;

Bazov, Jenny ;

Youngren, Jack ;

Paris, Pamela ;

Thomas, George ;

Small, Eric J. ;

Wang, Yuzhuo ;

Gleave, Martin E. ;

Collins, Colin C. ;

Chi, Kim N. .

CLINICAL CANCER RESEARCH, 2015, 21 (10) :2315-2324

[12] Overcoming mutation-based resistance to antiandrogens with rational drug design [J].

Balbas, Minna D. ;

Evans, Michael J. ;

Hosfield, David J. ;

Wongvipat, John ;

Arora, Vivek K. ;

Watson, Philip A. ;

Chen, Yu ;

Greene, Geoffrey L. ;

Shen, Yang ;

Sawyers, Charles L. .

ELIFE, 2013, 2

[13] Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α,17β-diol to 5α-dihydrotestosterone:: A potential therapeutic target for androgen-dependent disease [J].

Bauman, DR ;

Steckelbroeck, S ;

Williams, MV ;

Peehl, DM ;

Penning, TM .

MOLECULAR ENDOCRINOLOGY, 2006, 20 (02) :444-458

[14] Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer [J].

Beltran, Himisha ;

Prandi, Davide ;

Mosquera, Juan Miguel ;

Benelli, Matteo ;

Puca, Loredana ;

Cyrta, Joanna ;

Marotz, Clarisse ;

Giannopoulou, Eugenia ;

Chakravarthi, Balabhadrapatruni V. S. K. ;

Varambally, Sooryanarayana ;

Tomlins, Scott A. ;

Nanus, David M. ;

Tagawa, Scott T. ;

Van Allen, Eliezer M. ;

Elemento, Olivier ;

Sboner, Andrea ;

Garraway, Levi A. ;

Rubin, Mark A. ;

Demichelis, Francesca .

NATURE MEDICINE, 2016, 22 (03) :298-305

[15] Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity [J].

Beltran, Himisha ;

Yelensky, Roman ;

Frampton, Garrett M. ;

Park, Kyung ;

Downing, Sean R. ;

MacDonald, Theresa Y. ;

Jarosz, Mirna ;

Lipson, Doron ;

Tagawa, Scott T. ;

Nanus, David M. ;

Stephens, Philip J. ;

Mosquera, Juan Miguel ;

Cronin, Maureen T. ;

Rubin, Mark A. .

EUROPEAN UROLOGY, 2013, 63 (05) :920-926

[16] Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets [J].

Beltran, Himisha ;

Rickman, David S. ;

Park, Kyung ;

Chae, Sung Suk ;

Sboner, Andrea ;

MacDonald, Theresa Y. ;

Wang, Yuwei ;

Sheikh, Karen L. ;

Terry, Stephane ;

Tagawa, Scott T. ;

Dhir, Rajiv ;

Nelson, Joel B. ;

de la Taille, Alexandre ;

Allory, Yves ;

Gerstein, Mark B. ;

Perner, Sven ;

Pienta, Kenneth J. ;

Chinnaiyan, Arul M. ;

Wang, Yuzhuo ;

Collins, Colin C. ;

Gleave, Martin E. ;

Demichelis, Francesca ;

Nanus, David M. ;

Rubin, Mark A. .

CANCER DISCOVERY, 2011, 1 (06) :487-495

[17]

Bevan CL, 1999, MOL CELL BIOL, V19, P8383

[18] The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer [J].

Bishop, Jennifer L. ;

Thaper, Daksh ;

Vahid, Sepideh ;

Davies, Alastair ;

Ketola, Kirsi ;

Kuruma, Hidetoshi ;

Jama, Randy ;

Nip, Ka Mun ;

Angeles, Arkhjamil ;

Johnson, Fraser ;

Wyatt, Alexander W. ;

Fazli, Ladan ;

Gleave, Martin E. ;

Lin, Dong ;

Rubin, Mark A. ;

Collins, Colin C. ;

Wang, Yuzhuo ;

Beltran, Himisha ;

Zoubeidi, Amina .

CANCER DISCOVERY, 2017, 7 (01) :54-71

[19] Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors [J].

Cai, Changmeng ;

Chen, Sen ;

Ng, Patrick ;

Bubley, Glenn J. ;

Nelson, Peter S. ;

Mostaghel, Elahe A. ;

Marck, Brett ;

Matsumoto, Alvin M. ;

Simon, Nicholas I. ;

Wang, Hongyun ;

Chen, Shaoyong ;

Balk, Steven P. .

CANCER RESEARCH, 2011, 71 (20) :6503-6513

[20] Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal [J].

Chan, Siu Chiu ;

Li, Yingming ;

Dehm, Scott M. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (23) :19736-19749

← 1 2 3 4 5 6 7 8 9 →